The benefits of the multi-target approach in drug design and discovery

被引：130

作者：

Espinoza-Fonseca, LM ^{[1
]}

机构：

[1] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2006年 / 14卷 / 04期

关键词：

drug design; promiscuous drug; cancer; Alzheimer's disease;

D O I：

10.1016/j.bmc.2005.09.011

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Promiscuous binding has been considered to be a problem in the design and development of new drugs against a given disease. However, promiscuity in Molecular recognition is not all bad news, and scientists are currently taking advantage of the emerging 'promiscuous binding' or 'multi-target approach' in medicinal chemistry. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：896 / 897

页数：2

共 7 条

[1] Promiscuous anticancer drugs that hit multiple targets may thwart resistance [J].

Hampton, T .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (04) :419-+

[2] Multiple diverse ligands binding at a single protein site: A matter of pre-existing populations [J].

Ma, BY ;

Shatsky, M ;

Wolfson, HJ ;

Nussinov, R .

PROTEIN SCIENCE, 2002, 11 (02) :184-197

[3] Pathways towards and away from Alzheimer's disease [J].

Mattson, MP .

NATURE, 2004, 430 (7000) :631-639

[4] Promiscuity: what protects us, perplexes us [J].

Redinbo, MR .

DRUG DISCOVERY TODAY, 2004, 9 (10) :431-432

[5] The "promiscuous drug concept" with applications to Alzheimer's disease [J].

Stephenson, VC ;

Heyding, RA ;

Weaver, DF .

FEBS LETTERS, 2005, 579 (06) :1338-1342

[6]

Van Regenmortel MHV, 1999, J MOL RECOGNIT, V12, P1, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<1::AID-JMR449>3.0.CO

[7]

2-P

← 1 →